Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD 2: Open-label phase 2 patiromer dose-finding and safety study in children under 6 years with hyperkalemia
MOH_2023-08-15_012675Phase 2Not yet recruiting
- Sponsor
- Vifor Pharma
- Start
- Jan 2023
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of patiromer in hyperkalemia (2 cohorts), sponsored by Vifor Pharma. Primary endpoints: Change in serum potassium from baseline to Day 28 and Safety and tolerability of patiromer. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on MOH_2023-08-15_012675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-08-15_012675.